phase 1 clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion (vol 10, pg 28, 2012)

被引：0
|
作者：
Hamilton, Erika [1 ]
Blackwell, Kimberly [1 ]
Hobeika, Amy C. [2 ]
Clay, Timothy M. [3 ]
Broadwater, Gloria [4 ]
Ren, Xiu-Rong [5 ]
Chen, Wei [5 ]
Castro, Henry [3 ]
Lehmann, Frederic [3 ]
Spector, Neil [1 ]
Wei, Junping [6 ]
Osada, Takuya [6 ]
Lyerly, H. Kim [2 ]
Morse, Michael A. [1 ]
机构：
[1] Duke Univ, Med Ctr, Dept Med, Div Med Oncol, Durham, NC 27710 USA
[2] Duke Univ, Med Ctr, Dept Surg, Div Gen Surg, Durham, NC 27710 USA
[3] GlaxoSmithKline Biol, Rixensart, Belgium
[4] Duke Canc Inst, Canc Stat Ctr, Durham, NC USA
[5] Duke Univ, Med Ctr, Dept Med, Div Gastroenterol, Durham, NC 27710 USA
[6] Duke Univ, Med Ctr, Dept Surg, Div Surg Sci, Durham, NC 27710 USA
来源：
JOURNAL OF TRANSLATIONAL MEDICINE | 2013年 / 11卷
关键词：
D O I：
10.1186/1479-5876-11-82
中图分类号：
R-3 [医学研究方法]; R3 [基础医学];
学科分类号：
1001 ;
摘要：
[No abstract available]
引用
收藏
页数：1
相关论文
共 50 条
  • [11] HER2-specific Affibody Molecule [99mTc]Tc-ZHER2:41071: phase I clinical trial
    Tolmachev, V.
    Bragina, O.
    Larkina, M.
    Rybina, A.
    Zelchan, R.
    Oroujeni, M.
    Loftenius, A.
    Orlova, A.
    Sorensen, J.
    Frejd, F.
    Chernov, V.
    EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING, 2023, 50 (SUPPL 1) : S264 - S264
  • [12] The interplay of HER2/HER3/PI3K and EGFR/HER2/PLC-γ1 signalling in breast cancer cell migration and dissemination (vol 227, pg 234, 2012)
    Balz, L. M.
    JOURNAL OF PATHOLOGY, 2013, 230 (01): : e1 - e1
  • [13] Targeting HER2 aberrations as actionable drivers in lung cancers: phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2 - mutant or amplified tumors
    Kris, M. G.
    Camidge, D. R.
    Giaccone, G.
    Hida, T.
    Li, B. T.
    O'Connell, J.
    Taylor, I.
    Zhang, H.
    Arcila, M. E.
    Goldberg, Z.
    Jaenne, P. A.
    ANNALS OF ONCOLOGY, 2015, 26 (07) : 1421 - 1427
  • [14] Beamion Lung 1, a Phase Ia/Ib Trial of the HER2 TKI, BI 1810631 in Patients with Advanced Solid Tumors with HER2 Aberrations
    Yamamoto, N.
    Opdam, F.
    Barve, M.
    Tu, H. -Y.
    Wu, Y. -L.
    Schroeter, L.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Heymach, J.
    JOURNAL OF THORACIC ONCOLOGY, 2023, 18 (11) : S147 - S147
  • [15] A Phase I trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations
    Opdam, F.
    Heymach, J.
    Barve, M.
    Wu, Y. L.
    Gibson, N.
    Sadrolhefazi, B.
    Serra, J.
    Yoh, K.
    Yamamoto, N.
    EUROPEAN JOURNAL OF CANCER, 2022, 174 : S1 - S1
  • [16] Beamion LUNG-1: Phase Ia/b Trial of HER2 Tyrosine Kinase Inhibitor Zongertinib (BI 1810631) in Patients with HER2 Aberration-Positive Solid Tumors
    Heymach, John
    Yamamoto, Noboru
    Opdam, Frans
    Barve, Minal
    Tu, Hai-Yan
    Wu, Yi-Long
    Schroeter, Lukas
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Berz, David
    JOURNAL OF THORACIC ONCOLOGY, 2024, 19 (07) : E1 - E1
  • [17] CLINICAL ACTIVITY OF BIBW 2992, AN IRREVERSIBLE INHIBITOR OF EGFR/HER1 AND HER2 IN ADENOCARCINOMA OF THE LUNG WITH MUTATIONS IN THE KINASE DOMAIN OF HER2NEU
    De Greve, J.
    Decoster, L.
    De Mey, J.
    In 't Veld, P.
    Geers, C.
    Taton, M.
    Shahidi, M.
    Galdermans, D.
    Teugels, E.
    Schallier, D.
    JOURNAL OF THORACIC ONCOLOGY, 2010, 5 (05) : S90 - S91
  • [18] Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial.
    Zhu, Yajing
    Wang, Kang
    Zerdes, Ioannis
    Matikas, Alexios
    Bergqvist, Mattias
    Elinder, Ellinor
    Bosch, Ana
    Lindman, Henrik
    Einbeigi, Zakaria
    Andersson, Anne
    Carlsson, Lena
    Dreifaldt, Ann Charlotte
    Isaksson-Friman, Erika
    Hellstrom, Mats
    Johansson, Hemming
    Bergh, Jonas C. S.
    Hatschek, Thomas
    Foukakis, Theodoros
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [19] Clinical trial of HER2 cancer vaccine shows benefit in 45% of evaluable patients in phase 1 study
    Berzofsky, Jay
    Wood, Lauren
    Maeng, Hoyoung
    Trepel, Jane
    Stroncek, David
    Morris, John
    JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2019, 81 : 38 - 38
  • [20] Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data
    Heymach, John
    Opdam, Frans
    Barve, Minal A.
    Tu, Hai-Yan
    Wu, Yi-Long
    Berz, David
    Rohrbacher, Maren
    Sadrolhefazi, Behbood
    Serra, Josep
    Yoh, Kiyotaka
    Yamamoto, Noboru
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
12345